Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Recursion Pharmaceuticals, Inc. (RXRX) is offering 61,540,000 Class A common shares at $3.25 each, for a total offering price of $200,005,000. Estimated net proceeds are approximately $187.2 million after underwriting discounts and commissions and estimated offering expenses. The company intends to use proceeds for preclinical and clinical programs, platform technologies, runway extension, strategic investments and acquisitions, and general corporate purposes.
Preliminary cash, cash equivalents and restricted cash were approximately $561 million as of September 30, 2026, subject to closing procedures and quarterly review. Recursion expects its existing cash resources plus offering proceeds to fund operating expenses and capital expenditures into 2029. The offering states immediate dilution of approximately $2.21 per share in net tangible book value for new investors.
REC-4881 showed a 47% median reduction in total polyp burden at week 13 among 16 efficacy-evaluable patients; 85% (11 of 13) remained below baseline after 12 weeks off treatment. For REC-1245, 11 of 12 patients who started at 45 mg or 65 mg achieved disease control at eight weeks; Recursion selected 45 mg for monotherapy expansion. Sanofi optioned a first development candidate from its collaboration with Recursion, triggering a $10 million milestone; Recursion remains eligible for more than $300 million in additional program milestones.
Recursion Pharmaceuticals, Inc. (RXRX) priced a company-issued offering of 61,540,000 Class A common shares at $3.25 per share, with gross proceeds expected to be approximately $200 million before underwriting discounts, commissions and expenses. Closing is expected October 16, 2026, subject to customary conditions.
Preliminary cash, cash equivalents and restricted cash were approximately $561 million as of September 30, 2026, including approximately $86 million of net proceeds from the at-the-market program during the quarter. Recursion expects cash, including the offering’s net proceeds, to fund operating expenses and capital expenditures into 2029.
Sanofi optioned its first candidate from the collaboration, triggering a $10 million milestone and bringing total upfront and milestone payments to $144 million. Recursion remains eligible for more than $300 million in additional program milestones and an average of low double-digit royalties on net product sales if successfully commercialized; Sanofi will fund and lead development, with Phase 1 expected in 2027. REC-4881 showed a 47% median polyp-burden reduction after 12 weeks; 85% remained below baseline after 12 weeks off treatment. For REC-1245, 11 of 12 patients starting at 45 mg or 65 mg had disease control at eight weeks. The 45 mg expansion dose was selected; at 65 mg, 3 of 4 patients evaluable for dose-limiting toxicities had them, and the maximum tolerated dose was exceeded.
Recursion Pharmaceuticals, Inc. (RXRX) is offering $200,000,000 of Class A common stock. It intends to use net proceeds for preclinical and clinical programs, platform technologies, runway extension, strategic investments and acquisitions, and general corporate purposes. Recursion expects existing cash and offering proceeds to fund operating expenses and capital requirements into 2029.
Preliminary cash, cash equivalents and restricted cash were approximately $561 million as of September 30, 2026, including approximately $86 million in net proceeds from 23,696,330 shares sold through its at-the-market program during the quarter. Sanofi optioned a development candidate, triggering a $10 million milestone and bringing collaboration upfront and milestone payments to $144 million to date. Recursion remains eligible for more than $300 million in additional milestones and low-double-digit average royalties on net product sales if the candidate is successfully commercialized.
In REC-4881, 16 efficacy-evaluable patients had a 47% median reduction in total polyp burden at week 13; 85% (11 of 13) remained below baseline after twelve weeks off treatment. In REC-1245, 11 of 12 patients starting at 45 mg or 65 mg achieved disease control at eight weeks, and 45 mg daily was selected for monotherapy expansion.
Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 50,000 shares of Class A common stock on October 6, 2026, at a weighted average price of $4.84 per share. The sale was made under a Rule 10b5-1 trading plan adopted August 31, 2025; the shares were sold in multiple trades at prices ranging from $4.80 to $5.00. Direct holdings following the sale were 6,108,287 shares.
Recursion Pharmaceuticals, Inc. director Robert Hershberg exercised options covering 25,000 Class A common shares at $2.22 per share on October 6, 2026, acquired those shares, and sold 25,000 shares at $5.00 per share that day. The acquisition was pursuant to a Rule 10b5-1 trading plan adopted December 17, 2025. After the exercise, his reported option position covered 500,000 shares, with a $2.22 exercise price and a March 19, 2030 expiration date.
Recursion Pharmaceuticals, Inc. (RXRX) reports that Director Blake C. Borgeson intends to sell 50,000 Class A shares through Fidelity Brokerage Services LLC, at an aggregate market value of $242,000.00. The notice gives October 6, 2026, as the approximate sale date. It also lists three Class A sales by Borgeson during the preceding three months: 40,000 shares on July 7, 2026; 30,000 on August 4, 2026; and 30,000 on September 1, 2026.
Recursion Pharmaceuticals, Inc. (RXRX) director Robert M. Hershberg gave notice of a proposed sale of 25,000 Class A shares on October 6, 2026, with an aggregate market value of $125,000. The notice lists the shares as acquired from the issuer through a stock option exercise and sold for cash through Fidelity Brokerage Services LLC. The issuer's shares outstanding are listed as 535,342,170.
Recursion Pharmaceuticals, Inc. director Zavain Dar acquired 4,607 shares of Class A Common Stock on October 1, 2026, as an award issued pursuant to the issuer’s Outside Director Compensation Policy. The reported transaction price was 0.0000 per share. After the award, Zavain Dar’s directly held position was 245,371 shares.
Recursion Pharmaceuticals, Inc. director Dean Y. Li acquired 3,378 shares of Class A common stock on October 1, 2026, as an award issued pursuant to the issuer’s Outside Director Compensation Policy. His directly held position following the award was 1,476,707 shares. The report also lists 1,422,048 shares held by Dean Y. Li Revocable Trust and 421,000 shares held by Dean Y. Li 2021 Family Trust.
Recursion Pharmaceuticals, Inc. (RXRX) updated its relationship with Tempus AI, Inc. by amending their existing Master Agreement and signing a new RNA foundation model license. The amendment extends the data-access agreement term from five to six years, removes Recursion’s right to terminate for convenience, and lowers future Annual License Fees. Those fees are now $14,000,000 on each of the third, fourth and fifth anniversaries of the Effective Date, with at least $4,000,000 paid in cash and the remainder payable in cash or Class A common stock at Recursion’s election, while also decreasing the aggregate total of unique de-identified records Recursion may access.
Separately, Recursion granted Tempus a non-exclusive, non-sublicensable, non-transferable, worldwide license to its TxFM RNA foundation model for use in oncology. In return, Tempus will pay a non-refundable $12,000,000 license fee in two installments of $6,000,000 and will provide Recursion access to certain de-identified pathology records with linked clinical data during the TxFM License Agreement’s two-year term.